IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of “Moderate Buy” by Analysts

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has earned an average rating of “Moderate Buy” from the seventeen research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $50.6875.

Several equities research analysts have commented on the company. The Goldman Sachs Group boosted their target price on IDEAYA Biosciences from $31.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, April 14th. Mizuho lowered their price target on IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Royal Bank Of Canada upped their price target on IDEAYA Biosciences from $49.00 to $53.00 and gave the company an “outperform” rating in a report on Tuesday, April 14th. Wedbush reaffirmed an “outperform” rating and set a $58.00 price target on shares of IDEAYA Biosciences in a report on Tuesday. Finally, Guggenheim upped their price target on IDEAYA Biosciences from $50.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, April 14th.

IDEAYA Biosciences Trading Down 3.2%

IDEAYA Biosciences stock opened at $28.29 on Monday. The business’s fifty day simple moving average is $30.19 and its two-hundred day simple moving average is $32.64. IDEAYA Biosciences has a 12 month low of $20.50 and a 12 month high of $39.28. The company has a market capitalization of $2.49 billion, a price-to-earnings ratio of -17.68 and a beta of -0.05.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Tuesday, May 5th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.04). The business had revenue of $6.56 million during the quarter, compared to analyst estimates of $5.04 million. During the same quarter last year, the business earned ($0.82) earnings per share. The company’s quarterly revenue was down 39.4% on a year-over-year basis. On average, equities research analysts predict that IDEAYA Biosciences will post -4.27 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of IDYA. GSK plc bought a new position in shares of IDEAYA Biosciences during the fourth quarter valued at $46,093,000. Baker BROS. Advisors LP increased its position in IDEAYA Biosciences by 54.6% during the third quarter. Baker BROS. Advisors LP now owns 3,275,444 shares of the company’s stock valued at $89,125,000 after acquiring an additional 1,156,716 shares during the last quarter. State Street Corp increased its position in IDEAYA Biosciences by 27.6% during the fourth quarter. State Street Corp now owns 4,134,641 shares of the company’s stock valued at $142,935,000 after acquiring an additional 893,707 shares during the last quarter. Janus Henderson Group PLC increased its position in IDEAYA Biosciences by 11.8% during the fourth quarter. Janus Henderson Group PLC now owns 7,186,456 shares of the company’s stock valued at $248,344,000 after acquiring an additional 758,117 shares during the last quarter. Finally, First Turn Management LLC purchased a new stake in IDEAYA Biosciences during the fourth quarter valued at $25,017,000. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.